Haleon plc
HLNHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHaleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa,. Valued at $45.16B, HLN is a large-cap name in its sector. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.
Market Cap
$45.16B
Beta
0.28
P/E (TTM)
20.96
P/E (Fwd)
16.63
EPS (TTM)
$0.49
EPS (Fwd)
$0.62
ROE
10.1%
ROA
5.1%
Cash
$826.0M
Total Debt
$8.25B
Free CF
$1.80B
52W Change
11.6%
Annual Financials
Cash vs Debt
Where HLN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HLN finished 6.96% above its 150-day moving average ($9.48) and 4.75% above its 200-day moving average ($9.68). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HLN overbought or oversold?
At the October 20, 2026 close, HLN's RSI(14) was 78.3, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Haleon plc carries $8.25B in total debt against $826.0M in cash reserves — debt is roughly 10.0x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $1.80B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 10.1% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $9.54B to $11.03B.
HLN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HLN.